Charles River Laboratories and Autolomous Launch Apollo Orchestrate to Digitize GMP Laboratory Workflows
WILMINGTON, Mass. — Charles River Laboratories International, a global leader in providing essential drug discovery and development services, has officially launched “Apollo Orchestrate,” a cutting-edge digital capability designed to revolutionize laboratory execution. Developed in collaboration with Autolomous, the new platform integrates Autolomous’ proprietary autoloMATE digital Laboratory Execution System (LES) into Charles River’s existing Apollo ecosystem.
This strategic deployment marks a significant milestone in Charles River’s ongoing modernization strategy. By transitioning from traditional, paper-based documentation to a fully digitized, automated workflow, the company aims to enhance the speed, accuracy, and transparency of its Good Manufacturing Practice (GMP) quality control (QC) testing.
Apollo Orchestrate serves as a digital bridge between Charles River’s laboratory systems, including the Apollo platform and LabWare LIMS. The system provides end-to-end digital traceability, tracking the lifecycle of a sample from its initial submission through to laboratory execution and final release. This seamless integration ensures that data remains consistent and accessible, drastically reducing the risks associated with fragmented, manual systems.
“Aligned with our modernization strategy, it is crucial that we evolve quickly to enhance efficiencies and ensure medicines reach patients swiftly and safely,” said Kerstin Dolph, Corporate Senior Vice President of Global Manufacturing at Charles River. “The launch of Apollo Orchestrate, built on Autolomous’ autoloMATE platform, will increase efficiency while providing greater transparency and collaboration for our clients, both of which are key to our strategic goals.”
The implementation of Apollo Orchestrate is designed to shift the burden of administrative oversight away from technical and Quality Assurance (QA) teams. By minimizing manual data entry and automating workflows, the system reduces the potential for human error and audit risks. Consequently, personnel can redirect their efforts toward higher-value activities, such as scientific analysis and client-focused quality initiatives.
Alexander Seyf, CEO of Autolomous, emphasized the necessity of this digital shift in the life sciences sector. “Biological testing proves that a medicine is safe, effective, and ready for patients, but data collection and management across fragmented, often manual and paper-based systems from R&D to commercial release create unnecessary delays, opportunities for errors, and audit risks,” Seyf stated. “We designed autoloMATE to enable life sciences companies to connect that data directly into an integrated, digitized workflow.”
The rollout is currently underway at Charles River Biologics Testing Solutions sites across North America and Europe. The initial phase focuses on establishing a standardized and scalable operating model within GMP QC testing. Once these pilot programs are successfully established, Charles River intends to expand the technology across its broader global network of Biologics Testing Solutions facilities.
As the pharmaceutical industry faces increasing pressure to bring life-saving therapies to market faster, the partnership between Charles River and Autolomous represents a critical step toward the digital transformation of the pharmaceutical supply chain, promising a future of higher accuracy and improved patient outcomes.
Disclaimer: This content is auto-generated for informational purposes only.
Source: Read Original News
